| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Krzysztof Łabuzek | Q55390540 |
| Bogusław Okopień | Q57089603 | ||
| Michał Kozłowski | Q67220076 | ||
| Dawid Szkudłapski | Q125364993 | ||
| P2093 | author name string | Monika Kozłowska | |
| Patrycja Sikorska | |||
| P433 | issue | 3 | |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 207-212 | |
| P577 | publication date | 2013-01-31 | |
| P1433 | published in | European Journal of Internal Medicine | Q15716603 |
| P1476 | title | Incretin-based therapies in the treatment of type 2 diabetes--more than meets the eye? | |
| P478 | volume | 24 |
| Q38388920 | An updated review on cancer risk associated with incretin mimetics and enhancers |
| Q38250719 | Antihyperglycaemic therapies and cancer risk |
| Q33608038 | Cancer biology in diabetes |
| Q35964678 | Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins |
| Q51334791 | Distal gastrectomy in pancreaticoduodenectomy is associated with accelerated gastric emptying, enhanced postprandial release of GLP-1, and improved insulin sensitivity. |
| Q38101993 | Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis |
| Q35870409 | Impaired glucose metabolism treatment and carcinogenesis. |
| Q36635502 | Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study |
| Q42921290 | Incretin-based therapies: facing the realities of benefits versus side effects |
| Q57673205 | Obesity and Type 2 Diabetes |
| Q38213126 | Optimal utilisation of sulphonylureas in resource-constrained settings |
| Q38286444 | Potential side effects to GLP-1 agonists: understanding their safety and tolerability |
| Q21145700 | Structure-guided design of selective Epac1 and Epac2 agonists |
Search more.